Compumedics Limited revised earnings guidance for the fiscal year 2022. Revenues are expected to be about $37 million, subject to audit, which is a 4% increase over fiscal year 2021. Subject to finalisation of results and audit, EBITDA should be similar or better than fiscal year 2021, which was $2.6 million.

This is all in-line or slightly better than Guidance given on 27 May 2022.